SynthesisFrontiers in oncology2023

Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis.

Fabrice Yves Ndjana Lessomo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.